Roswell Park Comprehensive Cancer Center
Roswell Park Comprehensive Cancer Center makes three appointments
Roswell Park Comprehensive Cancer Center appointed three people to new roles in key areas of clinical care.
Goodbye, Clara
I’m still processing the fact that I won’t get to spend time with Clara Derber Bloomfield, MD, again.
Gabapentin shows efficacy as opioid alternative for patients with head and neck cancer
For many patients with head and neck cancer, treatment-associated oral mucositis is a source of severe pain.
National Comprehensive Cancer Network postpones conference due to COVID-19 concerns
National Comprehensive Cancer Network postponed its annual conference in response to concerns about the novel coronavirus, also known as COVID-19.
Antioxidant supplements linked to increased risk for breast cancer recurrence, death
Use of antioxidant supplements during chemotherapy, as well as iron and vitamin B12, by patients with breast cancer may increase their risk for disease recurrence and death, according to results of a prospective study published in Journal of Clinical Oncology.
Cancer drug doses: More is not always better
Historically, the goal of cancer treatment has been to destroy as many cancer cells as possible through chemotherapy or radiation.
Propensity score analysis supports blinatumomab vs. standard of care for relapsed/refractory ALL subset
Blinatumomab appeared to confer better outcomes than standard of care among adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia, according to results of a propensity score analysis published in Cancer.
T-cell Responses to Concurrent HIV and Herpesvirus Infections
An observational, prospective cohort study to discover new information about how HIV and herpes viruses interact with the immune system, with a goal of learning more about how T cells in the immune system respond to and fight off long-term (chronic) viruses, in order to improve medical care in the future.
TCR-engineered T Cells in Solid Tumors (ACTengine)
NY-ESO-1 TCR Engineered T Cell and HSC After Melphalan Conditioning Regimen in Treating Participants with Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1, open-label study evaluating the safety and efficacy of adoptive transfer of autologous NY-ESO-1 CD8-TCR engineered T cells and NY-ESO-1 CD4-TCR engineered hematopoietic stem cells after a myeloablative conditioning regimen, with administration of IL-2 in patients with relapsed or treatment-refractory ovarian, fallopian tube or primary peritoneal cancer.